FIELD: biotechnology.
SUBSTANCE: humanised monoclonal antibody against TNF and its application are described.
EFFECT: invention enables to reduce significantly the immunogenicity of murine antibody while maintaining the ability of the antibody to recognise the antigen as compared with the conservative chimeric murine antibody, increased antibody safety in clinical applications.
11 cl, 3 dwg, 5 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| ISOLATED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, ISOLATED NUCLEIC ACID (VARIANTS), RECOMBINANT EXPRESSION VECTOR, USING HOST-CELLS FOR EXPRESSION OF ANTIBODY AND METHOD FOR ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF ACTIVITY OF HUMAN TNFα | 1997 |
|
RU2268266C2 |
| METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNF ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT | 1997 |
|
RU2270030C2 |
| ANTI-PD-1 ANTIBODIES | 2015 |
|
RU2711141C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| METHODS AND COMPOSITIONS FOR DIAGNOSTICS OF ANKYLOSING SPONDYLITIS WITH APPLICATION OF BIO-MARKERS | 2006 |
|
RU2438704C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING MALIGNANT GROWTHS | 2009 |
|
RU2498819C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR PREVENTION | 2013 |
|
RU2631804C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2014 |
|
RU2678138C2 |
